Newbury Pharmaceuticals (NEWBRY) Q1 2025 earnings summary

Executive summary

• Q1 net revenue reached SEK 6,538k, down from SEK 11,185k year-over-year, with Nordic sales up 137% but no international shipments invoiced this quarter.

• EBITDA was SEK -3,759k compared to SEK -2,734k last year; operating cash flow turned positive at SEK 4,792k versus SEK -5,678k.

• Product launches in the Nordics increased to 13 from 4, and 23 products now have marketing authorization, up from 19.

• The company extended its SEK 15m loan to December 2025 and secured several new product approvals.

Financial highlights

• Net revenue for Q1 was SEK 6,538k, with no international sales (SEK 8,422k last year).

• EBITDA at SEK -3,759k; EBIT at SEK -4,229k; net result at SEK -4,638k.

• Cash at period end was SEK 19,431k, up from SEK 15,897k year-over-year.

• Equity at period end was SEK 46,773k (SEK 1.93/share); solidity 53%.

• Investments in portfolio development totaled SEK 664k, down from SEK 2,343k.

Outlook and guidance

• Continued focus on Nordic sales growth with more product launches expected in 2025.

• International sales expected to fluctuate, with orders on hand for 2025.

• Management remains confident in annual sales growth and ongoing portfolio expansion.